{"entity":{"type":"insider","cik":"0001883986","url":"/insider/0001883986","json_url":"/insider/0001883986.json","name":"Meisner Lara","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":19,"n_filings":12,"first":"2022-11-16","last":"2025-10-01","span_basis":"filed_date"},"name_variants":[{"name":"Meisner Lara","source":"filing","n_filings":12,"first_seen":"2022-11-16","last_seen":"2025-10-01"}],"transactions":[{"id":4644870,"accession":"0001883986-25-000009","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001883986-25-000009","line_url":"/filing/0001883986-25-000009#line-2","is_derivative":false,"issuer_cik":"0001883986","issuer_name":"Bicara Therapeutics Inc.","issuer_ticker":"BCAX","issuer_name_source":null,"issuer_url":"/issuer/0001883986","owner_cik":"0001883986","owner_name":"Meisner Lara","owner_display_name":"Meisner Lara","owner_url":"/insider/0001883986","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":33807.0,"shares_display":"33,807","price_per_share":14.75,"price_display":"14.75","price_state":"stated","total_value":498653.25,"total_display":"498,653.25","total_whole":"498,653","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-29","filed_date":"2025-10-01","scope":"insider"},{"id":4826558,"accession":"0001883986-25-000006","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001883986-25-000006","line_url":"/filing/0001883986-25-000006#line-2","is_derivative":false,"issuer_cik":"0001883986","issuer_name":"Bicara Therapeutics Inc.","issuer_ticker":"BCAX","issuer_name_source":null,"issuer_url":"/issuer/0001883986","owner_cik":"0001883986","owner_name":"Meisner Lara","owner_display_name":"Meisner Lara","owner_url":"/insider/0001883986","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15829.0,"shares_display":"15,829","price_per_share":11.49,"price_display":"11.49","price_state":"stated","total_value":181875.21,"total_display":"181,875.21","total_whole":"181,875","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-15","filed_date":"2025-09-17","scope":"insider"},{"id":5063260,"accession":"0002023658-25-000085","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0002023658-25-000085","line_url":"/filing/0002023658-25-000085#line-2","is_derivative":false,"issuer_cik":"0001883986","issuer_name":"Bicara Therapeutics Inc.","issuer_ticker":"BCAX","issuer_name_source":null,"issuer_url":"/issuer/0001883986","owner_cik":"0001883986","owner_name":"Meisner Lara","owner_display_name":"Meisner Lara","owner_url":"/insider/0001883986","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15829.0,"shares_display":"15,829","price_per_share":10.43,"price_display":"10.43","price_state":"stated","total_value":165096.47,"total_display":"165,096.47","total_whole":"165,096","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-16","filed_date":"2025-06-18","scope":"insider"},{"id":4583355,"accession":"0000950170-25-041546","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-041546","line_url":"/filing/0000950170-25-041546","is_derivative":false,"issuer_cik":"0001883986","issuer_name":"Bicara Therapeutics Inc.","issuer_ticker":"BCAX","issuer_name_source":null,"issuer_url":"/issuer/0001883986","owner_cik":"0001883986","owner_name":"Meisner Lara","owner_display_name":"Meisner Lara","owner_url":"/insider/0001883986","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":79146.0,"shares_display":"79,146","price_per_share":12.902873120561999,"price_display":"12.90","price_state":"stated","total_value":1021210.796,"total_display":"1,021,210.80","total_whole":"1,021,211","shares_owned_after":30620.0,"shares_owned_after_display":"30,620","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-14","filed_date":"2025-03-18","scope":"insider","n_lines":2},{"id":8644791,"accession":"0000899243-23-015998","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-23-015998","line_url":"/filing/0000899243-23-015998#line-4","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":"0001883986","owner_name":"Meisner Lara","owner_display_name":"Meisner Lara","owner_url":"/insider/0001883986","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":27.0,"shares_display":"27","price_per_share":28.35,"price_display":"28.35","price_state":"stated","total_value":765.45,"total_display":"765.45","total_whole":"765","shares_owned_after":29971.0,"shares_owned_after_display":"29,971","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-16","filed_date":"2023-06-20","scope":"insider"},{"id":8644783,"accession":"0000899243-23-015998","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-23-015998","line_url":"/filing/0000899243-23-015998#line-2","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":"0001883986","owner_name":"Meisner Lara","owner_display_name":"Meisner Lara","owner_url":"/insider/0001883986","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2269.0,"shares_display":"2,269","price_per_share":28.02,"price_display":"28.02","price_state":"stated","total_value":63577.38,"total_display":"63,577.38","total_whole":"63,577","shares_owned_after":29971.0,"shares_owned_after_display":"29,971","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-15","filed_date":"2023-06-20","scope":"insider"},{"id":8280154,"accession":"0000899243-23-014615","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-23-014615","line_url":"/filing/0000899243-23-014615#line-6","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":"0001883986","owner_name":"Meisner Lara","owner_display_name":"Meisner Lara","owner_url":"/insider/0001883986","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5126.0,"shares_display":"5,126","price_per_share":25.02,"price_display":"25.02","price_state":"stated","total_value":128252.52,"total_display":"128,252.52","total_whole":"128,253","shares_owned_after":29971.0,"shares_owned_after_display":"29,971","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-06","filed_date":"2023-06-06","scope":"insider"},{"id":8280144,"accession":"0000899243-23-014615","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-23-014615","line_url":"/filing/0000899243-23-014615#line-4","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":"0001883986","owner_name":"Meisner Lara","owner_display_name":"Meisner Lara","owner_url":"/insider/0001883986","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":499.0,"shares_display":"499","price_per_share":25.03,"price_display":"25.03","price_state":"stated","total_value":12489.97,"total_display":"12,489.97","total_whole":"12,490","shares_owned_after":29971.0,"shares_owned_after_display":"29,971","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-05","filed_date":"2023-06-06","scope":"insider"},{"id":8280131,"accession":"0000899243-23-014615","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-23-014615","line_url":"/filing/0000899243-23-014615#line-2","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":"0001883986","owner_name":"Meisner Lara","owner_display_name":"Meisner Lara","owner_url":"/insider/0001883986","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1875.0,"shares_display":"1,875","price_per_share":24.21,"price_display":"24.21","price_state":"stated","total_value":45393.75,"total_display":"45,393.75","total_whole":"45,394","shares_owned_after":29971.0,"shares_owned_after_display":"29,971","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-02","filed_date":"2023-06-06","scope":"insider"},{"id":8644407,"accession":"0000899243-23-007996","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-007996","line_url":"/filing/0000899243-23-007996#line-1","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":"0001883986","owner_name":"Meisner Lara","owner_display_name":"Meisner Lara","owner_url":"/insider/0001883986","role":"Officer (General Counsel and Secretary)","role_mark":"O","role_mark_label":"Officer (General Counsel and Secretary)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"General Counsel and Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":29971.0,"shares_display":"29,971","price_per_share":29.07,"price_display":"29.07","price_state":"stated","total_value":871256.97,"total_display":"871,256.97","total_whole":"871,257","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-09","filed_date":"2023-03-10","scope":"insider"},{"id":8213295,"accession":"0000899243-23-002674","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-23-002674","line_url":"/filing/0000899243-23-002674#line-3","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":"0001883986","owner_name":"Meisner Lara","owner_display_name":"Meisner Lara","owner_url":"/insider/0001883986","role":"Officer (General Counsel and Secretary)","role_mark":"O","role_mark_label":"Officer (General Counsel and Secretary)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"General Counsel and Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6843.0,"shares_display":"6,843","price_per_share":35.66,"price_display":"35.66","price_state":"stated","total_value":244021.38,"total_display":"244,021.38","total_whole":"244,021","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-23","filed_date":"2023-01-25","scope":"insider"},{"id":6945544,"accession":"0000899243-22-039217","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-22-039217","line_url":"/filing/0000899243-22-039217#line-4","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":"0001883986","owner_name":"Meisner Lara","owner_display_name":"Meisner Lara","owner_url":"/insider/0001883986","role":"Officer (General Counsel and Secretary)","role_mark":"O","role_mark_label":"Officer (General Counsel and Secretary)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"General Counsel and Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16326.0,"shares_display":"16,326","price_per_share":29.19,"price_display":"29.19","price_state":"stated","total_value":476555.94,"total_display":"476,555.94","total_whole":"476,556","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-21","filed_date":"2022-12-22","scope":"insider"},{"id":6945541,"accession":"0000899243-22-039217","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-039217","line_url":"/filing/0000899243-22-039217#line-2","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":"0001883986","owner_name":"Meisner Lara","owner_display_name":"Meisner Lara","owner_url":"/insider/0001883986","role":"Officer (General Counsel and Secretary)","role_mark":"O","role_mark_label":"Officer (General Counsel and Secretary)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"General Counsel and Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":600.0,"shares_display":"600","price_per_share":28.07,"price_display":"28.07","price_state":"stated","total_value":16842.0,"total_display":"16,842.00","total_whole":"16,842","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-20","filed_date":"2022-12-22","scope":"insider"},{"id":6878663,"accession":"0000899243-22-039056","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-22-039056","line_url":"/filing/0000899243-22-039056#line-4","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":"0001883986","owner_name":"Meisner Lara","owner_display_name":"Meisner Lara","owner_url":"/insider/0001883986","role":"Officer (General Counsel and Secretary)","role_mark":"O","role_mark_label":"Officer (General Counsel and Secretary)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"General Counsel and Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1297.0,"shares_display":"1,297","price_per_share":28.44,"price_display":"28.44","price_state":"stated","total_value":36886.68,"total_display":"36,886.68","total_whole":"36,887","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-16","filed_date":"2022-12-19","scope":"insider"},{"id":6878654,"accession":"0000899243-22-039056","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-039056","line_url":"/filing/0000899243-22-039056#line-2","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":"0001883986","owner_name":"Meisner Lara","owner_display_name":"Meisner Lara","owner_url":"/insider/0001883986","role":"Officer (General Counsel and Secretary)","role_mark":"O","role_mark_label":"Officer (General Counsel and Secretary)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"General Counsel and Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":300.0,"shares_display":"300","price_per_share":28.08,"price_display":"28.08","price_state":"stated","total_value":8424.0,"total_display":"8,424.00","total_whole":"8,424","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-15","filed_date":"2022-12-19","scope":"insider"},{"id":6510351,"accession":"0000899243-22-038520","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-22-038520","line_url":"/filing/0000899243-22-038520#line-4","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":"0001883986","owner_name":"Meisner Lara","owner_display_name":"Meisner Lara","owner_url":"/insider/0001883986","role":"Officer (General Counsel and Secretary)","role_mark":"O","role_mark_label":"Officer (General Counsel and Secretary)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"General Counsel and Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15656.0,"shares_display":"15,656","price_per_share":28.12,"price_display":"28.12","price_state":"stated","total_value":440246.72,"total_display":"440,246.72","total_whole":"440,247","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-14","filed_date":"2022-12-14","scope":"insider"},{"id":6510345,"accession":"0000899243-22-038520","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-038520","line_url":"/filing/0000899243-22-038520#line-2","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":"0001883986","owner_name":"Meisner Lara","owner_display_name":"Meisner Lara","owner_url":"/insider/0001883986","role":"Officer (General Counsel and Secretary)","role_mark":"O","role_mark_label":"Officer (General Counsel and Secretary)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"General Counsel and Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":600.0,"shares_display":"600","price_per_share":28.05,"price_display":"28.05","price_state":"stated","total_value":16830.0,"total_display":"16,830.00","total_whole":"16,830","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-12","filed_date":"2022-12-14","scope":"insider"},{"id":6201196,"accession":"0000899243-22-036044","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-036044","line_url":"/filing/0000899243-22-036044#line-2","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":"0001883986","owner_name":"Meisner Lara","owner_display_name":"Meisner Lara","owner_url":"/insider/0001883986","role":"Officer (General Counsel and Secretary)","role_mark":"O","role_mark_label":"Officer (General Counsel and Secretary)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"General Counsel and Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8125.0,"shares_display":"8,125","price_per_share":22.05,"price_display":"22.05","price_state":"stated","total_value":179156.25,"total_display":"179,156.25","total_whole":"179,156","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-15","filed_date":"2022-11-16","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":19,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":19,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":19},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0002023658","name":"Bicara Therapeutics Inc.","url":"/issuer/0002023658","role":"Officer (Chief Legal Officer)","n_filings":4,"first_seen":"2025-03-18","last_seen":"2025-10-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001590750","name":"Viridian Therapeutics, Inc.\\DE","url":"/issuer/0001590750","role":"Officer (Chief Legal Officer)","n_filings":8,"first_seen":"2022-11-16","last_seen":"2023-06-20"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001883986","retrieved_at":"2026-08-25T15:21:31+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}